BTK and head and neck squamous cell carcinoma: Thus, our data demonstrate a high potential to treat HNSCC patients with BTK inhibitors, either in combination with today’s applied standard-of-care therapies or with novel immunotherapeutic approaches, in order to improve the response to therapy and thus make it more satisfactory.